Media coverage about Patheon NV (NASDAQ:PTHN) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Patheon NV earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.3772340057605 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of analysts recently issued reports on PTHN shares. Jefferies Group LLC reaffirmed a “hold” rating and issued a $35.00 target price on shares of Patheon NV in a research report on Friday, July 21st. BidaskClub downgraded Patheon NV from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $33.60.

Patheon NV has a 12 month low of $23.72 and a 12 month high of $35.13.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/08/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-patheon-nv-pthn-stock-price.html.

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Insider Buying and Selling by Quarter for Patheon NV (NASDAQ:PTHN)

Receive News & Stock Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related stocks with our FREE daily email newsletter.